If you read my list of startups using artificial intelligence in drug discovery, you may have wondered: how much traction do these companies actually have? And perhaps, if you work for a pharmaceutical or biotechnology company, a related question: are any of my competitors working with them?

To help answer such questions, this post summarizes how pharmaceutical companies apply artificial intelligence in drug discovery, including through partnerships with AI startups. As with my startup list, I aim to keep this regularly updated. So if I'm missing anything (which I certainly am, because details of partnerships are often kept secret), or you have news to share, please email me. Or post in the comments.

Here's the list:

Contents

1. AbbVie
2. Almirall
3. Amgen
4. Astellas
5. AstraZeneca
6. BASF
7. Bayer
8. Boehringer Ingelheim
9. Bristol-Myers Squibb (BMS)
10. CJ Healthcare
11. Celgene
12. Daewoong Pharmaceutical
13. Eisai
14. Eli Lilly
15. Evotec
16. GSK
17. Genentech
18. Gilead
19. Ionis Pharmaceuticals
20. Ipsen
21. Janssen
22. Lundbeck
23. Merck KGaA
24. Merck and Co.
25. Mitsubishi Tanabe Pharma
26. Nestlé
27. Novartis
28. Novo Nordisk
29. Ono Pharmaceuticals
30. Pfizer
31. Procter & Gamble
32. Roche
33. SK Biopharmaceuticals
34. Sanofi
35. Santen
36. Servier
37. Sumitomo Dainippon Pharma
38. Sunovion
39. Takeda
40. Wave Life Sciences
41. WuXi AppTec
42. Yuhan Corp.
43. Zambon Pharma

Companies

AbbVie

AbbVie hasn't publicly promoted its use of AI as much as some other pharmaceutical companies. But I have met members of its AI team and seen presentations that convince me it's a leader. In particular, I've been impressed by AbbVie's practical use of AI for automation.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for AbbVie:

• AiCure: AbbVie used AiCure's AI-based patient monitoring platform to improve adherence in an phase 2 schizophrenia trial. I have learned that the partnership is now complete. ("AiCure announces new study results demonstrating 90% adherence from Phase 2 Abbvie study," 9/26/2016.)
• Atomwise: AbbVie is listed on the Atomwise partner page. There is little information about this partnership that I can find online. I have learned, however, that the partnership never really got going. ("Partners – Atomwise," 11/13/2019.)
• Calico: Since 2014, AbbVie has had a significant partnership with Calico, Alphabet's discovery-stage company focused on understanding the biology of aging. In a nutshell, AbbVie will help develop and commercialize Calico discoveries. I've added the partnership to this list because I've learned from people in the know that it involves machine learning, though the details aren't public. ("AbbVie and Calico Announce Extension of Groundbreaking Collaboration," 6/26/2018; "AbbVie and Calico Announce a Novel Collaboration to Accelerate the Discovery, Development, and Commercialization of New Therapies," 9/3/2014.)

Almirall

Almirall is a Spanish pharmaceutical company, with headquarters in Barcelona.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Almirall:

• Iktos: In December 2019, Iktos announced a partnership with Almirall to use its generative modelling technology to design novel optimized compounds and speed identification of promising drug candidates for undisclosed indications. ("Iktos and Almirall Announce Research Collaboration in Artificial Intelligence for New Drug Design," 12/12/2019.)

Amgen

Amgen also hasn't publicly promoted its use of AI as much as some other pharmaceutical companies. But I have seen presentations at conferences that convey unique and sophisticated application of machine learning. In particular, I was impressed by a process that Amgen is developing to generate novel biologic drugs with machine learning.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Amgen:

• GNS Healthcare: The investment arm of Amgen led a $6 million round of funding in GNS Healthcare. ("GNS Healthcare Adds $6M, Led by Amgen, for Machine Learning Tech," 8/23/2017.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Amgen is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): Amgen is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• Owkin: Articles describe Owkin as partnering with Amgen, though the full nature of the partnership isn't clear. ("GV invests in medical machine learning startup Owkin," 5/23/2018.)

Astellas

Astellas appears to be focusing AI drug discovery on repurposing existing compounds. It published a news release about "Drug Repurposing & Application Management" in February 2015, for example (this release is no longer available online). It also has a number of partnerships in the area of drug repurposing.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Astellas:

• Biovista: Biovista will explore new indications for a number of undisclosed Astellas compounds using its Clinical Outcome Search Space (COSS) technology. ("Biovista Inc. Announces Drug Repositioning Collaboration with Astellas Pharma," 12/2/2015.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Astellas is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• NuMedii: NuMedii will identify new indications for a number of undisclosed Astellas compounds using its "Big Data intelligence" technology. ("NuMedii, Inc. Announces New Indications Discovery Collaboration With Astellas," 1/11/2016.)

AstraZeneca

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for AstraZeneca:

• BenevolentAI: The partnership will focus on new drugs for chronic kidney disease and idiopathic pulmonary fibrosis. ("AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery," 4/30/2019.)
• Berg: Berg is collaborating with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson's disease. ("BERG Forms Research Collaboration with AstraZeneca to Identify New Therapeutic Targets to Treat Neurological Disorders such as Parkinson's Disease," 8/28/2017.)
• DeepMatter: In December 2019, articles reported that DeepMatter would provide its AI-driven compound synthesis platform to AstraZeneca. ("DeepMatter will help AstraZeneca digitise discovery chemistry," 12/9/2019.)
• Gatehouse Bio: In December 2019, Gatehouse Bio announced a partnership with AstraZeneca to explore the identification of new targets for respiratory and cardiovascular diseases using its AI-powered platform. Gatehouse uses AI to identify novel small RNA (sRNA) signatures and molecular pathways correlated with and potentially driving disease. Gatehouse had joined AstraZeneca's Boston Bio Hub Incubator in 2018. ("Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery," 12/9/2019.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): AstraZeneca is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• ProteinQure: In June 2019, I received a tip (see comments) that AstraZeneca, via subsidiary MedImmune, had established a multi-year collaboration with ProteinQure. The exact nature of this partnership isn't clear. ("ProteinQure | CANADIAN TECHNOLOGY ACCELERATOR," 6/11/2019.)
• Schrödinger: AstraZeneca is collaborating with Schrödinger to deploy its drug design platform, which combines physics-based modeling and machine learning, to identify new therapeutic candidates and improve the likelihood that synthesized compounds will have desired properties. ("Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery," 9/4/2019.)

BASF

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for BASF:

• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): BASF is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• Nuritas: Nuritas discovers natural peptides with health benefits. The startup partnered with BASF initially in January 2017. In November 2018, the pair announced the first peptide to be commercialized under the partnership: a natural ingredient from brown rice that reduces inflammation. ("Artificial Intelligence: BASF partner with Nuritas on 'next gen' functional peptides," 1/19/2017.)

Bayer

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Bayer:

• Alliance for Artificial Intelligence in Healthcare (AAIH): Evotec announced an initial collaboration with Exscientia in April 2016 and an investment in September 2017. The partnership focuses on creating bispecific small molecule immuno-oncology therapies. These are treatments that can hit two different cancer targets simultaneously. In January 2019, Evotec also announced participating in Exscientia's Series B. ("AAIH Announces Inaugural Board of Directors and Officers After Formal Launch," 1/22/2019.)
• Cyclica: Cyclica was included in Bayer's Grants4Apps program, and in November 2018 announced that Bayer was using its technology for off-target effect investigation, pharmacokinetic property prediction, and multi-targeted drug design. ("Cyclica Drives Drug Discovery Through AI-Augmented Integrated Network of Cloud-Based Technologies together with Bayer — Cyclica," 11/26/2018; "Cyclica Joins Bayer G4A to Advance its Novel Differential Drug Design Technology," 8/30/2018.)
• Exscientia: Bayer and Exscientia entered into a three-year collaboration in January 2020. The partnership aims to identify and optimize novel lead structures for cardiovascular and oncological diseases. ("Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery," 1/9/2020.)
• Genpact: Genpact worked with Bayer to apply AI to pharmacovigilance. Genpact's technology automatically extracts adverse event data from source documents. ("Bayer applies artificial intelligence to its pharmacovigilance systems -," 11/2/2018.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Bayer is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): Bayer is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• Schrödinger: In January 2020, Schrödinger and Bayer announced a five-year alliance to create a new solution for Bayer to enumerate, screen, and score synthetically feasible, virtual compounds. The software will combine Schrödinger’s physics-based modeling and machine learning technology with Bayer’s proprietary in silico models. ("Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery," 1/8/2020.)
• Sensyne Health: Bayer and Sensyne are collaborating to develop treatments for cardiovascular disease. Sensyne has a unique partnership with the NHS to leverage its electronic patient record data while protecting patient privacy. The partners also established the "LifeHub" project, focused on AI-enabled radiology and imaging. ("Sensyne Health Signs Collaboration Agreement with Bayer to Accelerate the Development of New Treatments for Cardiovascular Disease using Clinical Artificial Intelligence," 7/31/2019.)

Boehringer Ingelheim

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Boehringer Ingelheim:

• Healx: In December 2019, rare disease drug repurposing specialist Healx announced a partnership with BI to identify indications related to rare neurological diseases. Healx will look for new indications for assets in BI's pipeline. ("Healx Joins Forces with Boehringer Ingelheim to Discover New Treatment Approaches for Rare Neurological Diseases," 12/9/2019.)
• Kairntech: In January 2020, BI and AI software startup Kairntech announced "cooperation" leveraging Sherpa, Kairntech's platform for NLP. ("German Pharma Company Boehringer Ingelheim licenses AI/NLP Platform from Kairntech," 1/7/2020.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): BI is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• Nanna Therapeutics: BI will use Nanna's "Totally Integrated Medicines Engine" platform to identify novel small molecule lead compounds. Note: Nanna's previous name was "Bactevo." ("Boehringer partners with Bactevo on drug discovery - PMLiVE," 5/14/2018.)
• Numerate: One of the earliest AI drug discovery partnerships I could find predates the recent hype about machine learning. Between the Canadian arm of Boehringer Ingelheim and Numerate, it doesn't even refer to AI. The Numerate press release states that it is "leveraging the power of cloud computing and novel computational methods to transform the drug design process." The partnership is focused on generating small molecule drug leads for an unnamed infectious disease target. ("Numerate and Boehringer Ingelheim (Canada) Form Drug Discovery Collaboration," 12/6/2011.)

Bristol-Myers Squibb (BMS)

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Bristol-Myers Squibb (BMS):

• Concerto HealthAI: Concerto specializes in using AI to analyze real-world oncology data in order to generate insights and real-world evidence. Its partnership with BMS covers a range of data sources, cancers, and activities, including clinical trials, protocol design, and precision oncology treatments. ("Bristol-Myers Squibb and Concerto HealthAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations," 3/28/2019.)
• PathAI: In November 2019, PathAI announced investment from BMS and the Merck Global Health Innovation Fund (Merck GHIF) in its AI-powered pathology platform. ("PathAI Receives Investment from Merck and Bristol-Myers Squibb; Completes $75M Series B," 11/4/2019.)
• Sirenas: BMS partnered with Sirenas to apply the biotech company's technology to challenging therapeutic targets. Sirenas uses data mining and machine learning to find therapeutic applications of chemicals from global microbiome samples. ("Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb," 2/12/2018.)

CJ Healthcare

CJ HealthCare is a South Korean medical and biotechnology company, with headquarters in Seoul.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for CJ Healthcare:

• Standigm: In December 2019, Korean news sources reported that CJ Healthcare and Standigm were partnering to discovery new compounds for anticancer drugs using Standigm's AI platforms. ("CJ Healthcare unites with Standigm to develop AI-based anticancer drugs," 12/17/2019.)

Celgene

Bristol-Myers Squibb (BMS) acquired Celgene, so look there for future information. I'm keeping this here for historical reference.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Celgene:

• Exscientia: AI drug discovery startup Exscientia announced that Celgene invested in its Series B. A report in March 2019 said Celgene will have a three-year deal with Exscientia to use its AI in discovering small molecules for three targets. ("Evotec invests in financing round of Exscientia," 1/7/2019; "Exscientia Raises US$26 Million in Series B Financing Round to Accelerate Scaling as the Leading AI Drug Discovery Company," 1/7/2019; "Celgene taps Exscientia’s AI drug discovery tech for 3 new programs," 3/21/2019.)
• GNS Healthcare: Celgene is also an investor in precision medicine startup GNS Healthcare. ("Celgene Invests More in GNS Healthcare For Machine Learning Software," 11/29/2016.)

Daewoong Pharmaceutical

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Daewoong Pharmaceutical:

• A2A Pharmaceuticals: Daewoong and A2A announced in January 2020 that they were collaborating on up to three oncology drug targets. In the collaboration, A2A will use its computational drug discovery platform to design new compounds, Daewoong will synthesize and evaluate them, and both will participate in preclinical optimization and lead candidate selection. ("A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery," 1/14/2020.)

Eisai

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Eisai:

• Keio University: Eisai and Keio University in Japan announced a collaboration in December 2016 to discover and develop new drugs targeting dementia. One component of the collaboration is the use of artificial intelligence to determine new drug targets. ("Eisai and Keio University to Establish a New Industry-Academia Collaboration Site," 12/22/2016.)

Eli Lilly

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Eli Lilly:

• Atomwise: Atomwise announced a collaboration on up to 10 drugs with Lilly. It appears that Lilly will use Atomwise's technology to screen molecules that Lilly synthesizes for their therapeutic potential. ("Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program," 6/3/2019.)
• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): Eli Lilly is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• Strateos: Then known as Transcriptic, Strateos partnered with Eli Lilly in July 2018 to deploy its robotic lab technology that allows researchers worldwide to remotely design, synthesize, and screen investigational molecules. In January 2020, Lilly unveiled the lab, located in San Diego. ("Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab," 1/9/2020; "Transcriptic Selected to Oversee Robotic Cloud Lab Platform for Lilly’s San Diego Biotechnology Center," 7/24/2018.)

Evotec

Evotec refers to itself as a "drug discovery alliance and development partnership company." Its partners include many more well-known pharmaceutical companies, such as Bayer, Sanofi, Genentech, Janssen, and UCB.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Evotec:

• Exscientia: Evotec announced an initial collaboration with Exscientia in April 2016 and an investment in September 2017. The partnership focuses on creating bispecific small molecule immuno-oncology therapies. These are treatments that can hit two different cancer targets simultaneously. In January 2019, Evotec also announced participating in Exscientia's Series B. ("Evotec invests in financing round of Exscientia," 1/7/2019; "Evotec and Exscientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics," 4/26/2016; "Evotec invests in Exscientia to advance AI-driven drug discovery," 9/28/2017.)
• University of Oxford: Evotec has a partnership with the University of Oxford called LAB10x designed to move data-driven drug discovery projects out of academia. ("Evotec forms Oxford initiative to spawn AI-enabled startups," 6/24/2019.)

GSK

GSK has been one of the most active pharmaceutical companies in applying artificial intelligence to drug discovery. It was one of the first to create an in-house artificial intelligence unit. (Initially called "Medicines Discovered Using Artificial Intelligence.” Now called “In silico Drug Discovery Unit.”) As of July 2019, GSK's AI team reportedly numbered about 50. In December 2019, GSK announced that it was ramping up hiring AI specialists, with the goal of adding 80 in 2020.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for GSK:

• ATOM: GSK was the first pharmaceutical company to participate in the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, which aims to leverage artificial intelligence to go from drug target to patient-ready therapy in less than a year. (An ambitious goal.) GSK gave ATOM chemical and in vitro biological data for more than 2 million compounds it has screened. ("Public-private consortium aims to cut preclinical cancer drug discovery from six years to just one," 10/27/2017.)
• Alliance for Artificial Intelligence in Healthcare (AAIH): GSK is a founding member of the AAIH. ("AAIH Announces Inaugural Board of Directors and Officers After Formal Launch," 1/22/2019.)
• Cloud Pharmaceuticals: Cloud Pharmaceuticals is partnering with GSK to use AI for the design of novel small-molecule drugs. ("Cloud Pharmaceuticals forms Drug Design Collaboration with GSK," 5/30/2018.)
• Exscientia: GSK's partnership with Excscientia is to discover novel and selective small molecules for up to 10 disease-related targets across undisclosed therapeutic areas. In early April 2019, Exscientia announced that its partnership with GSK had produced its first tangible result: a "highly potent" lead molecule targeting a novel pathway for chronic obstructive pulmonary disease. ("Exscientia reaches first major milestone with GSK," 4/4/2019; "Exscientia Enters Strategic Drug Discovery Collaboration with GSK," 7/1/2017.)
• Google: While I didn't see any formal partnership announcement, GSK researchers have worked with Google researchers on applying AI to drug discovery, including to develop a machine learning algorithm to identify protein crystals. ("Classification of crystallization outcomes using deep convolutional neural networks," 6/20/2018.)
• Insilico Medicine: Insilico is partnering with GSK to identify novel biological targets and pathways. ("Insilico establishes collaboration with GSK to discover novel biological targets and molecules," 8/16/2017.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): GSK is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• University of Nottingham: GSK has a collaboration with researchers at the Universities of Strathclyde and Nottingham, announced in July 2019, that focuses on applying AI to synthetic chemistry. ("New partnership to accelerate drug discovery," 7/10/2019.)
• University of Strathclyde: See entry for University of Nottingham, above. ("New partnership to accelerate drug discovery," 7/10/2019.)

Genentech

In addition to what I've outlined below, in September 2019, Genentech and parent Roche disclosed a predictive analytics project with a paper in Nature on using deep learning to predict which patients with diabetic retinopathy will progress the fastest.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Genentech:

• GNS Healthcare: Genentech and precision medicine startup GNS Healthcare are partnering to find and validate potential cancer drug targets by analyzing data from sources such as electronic medical records and next generation sequencing. ("GNS Healthcare Announces Collaboration to Power Cancer Drug Development with REFS™ Causal Machine Learning and Simulation AI Platform," 6/19/2017.)

Gilead

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Gilead:

• Glympse Bio: In October 2019, Gilead and Glympse Bio announced a strategic collaboration in nonalcoholic steatohepatitis (NASH) that will leverage Glympse's AI-powered synthetic biomarkers to determine clinical trial participants’ stage of disease at initial screening, and their response to treatment. ("Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development," 10/28/2019.)
• Insitro: From what I can tell, Gilead's first publicly announced use of AI in drug discovery was its partnership with Insitro. Which was big news. The collaboration will focus on nonalcoholic steatohepatitis (NASH). Gilead will use Insitro's platform to create disease models for NASH and find targets that affect the disease's progression and regression. ("Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis," 4/16/2019.)

Ionis Pharmaceuticals

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Ionis Pharmaceuticals:

• Empirico: Empirico announced in January 2020 a strategic collaboration with Ionis, including a three-year partnership to identify therapeutic targets for indications and tissues that are amenable to Ionis' antisense technology. Ionis also made a $10 million equity investment in the company. ("Empirico Announces Strategic Collaboration to Harness Human Genetics for the Discovery and Development of Novel Antisense Oligonucleotide Therapeutics," 1/9/2020.)

Ipsen

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Ipsen:

• Owkin: According to news reports, Ipsen is working with medical research federated machine learning startup Owkin. ("GV invests in medical machine learning startup Owkin," 5/23/2018.)

Janssen

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Janssen:

• Alliance for Artificial Intelligence in Healthcare (AAIH): Janssen is a founding member of the AAIH. ("AAIH Announces Inaugural Board of Directors and Officers After Formal Launch," 1/22/2019.)
• BenevolentAI: One of the more unique AI drug development partnerships I've seen is that between Janssen and BenevolentAI. In November 2016, they announced that BenevolentAI would license the right to develop, manufacture, and commercialize clinical stage drug candidates from Janssen after using artificial intelligence to identify untapped potential in Janssen's portfolio. BenevolentAI launched a phase 2b trial for a drug from the partnership to treat sleepiness in people with Parkinson's disease. ("British Artificial Intelligence Firm Announces Exclusive License Agreement with Janssen for Clinical Stage Drug Candidates, Facilitated by Johnson & Johnson Innovation," 11/8/2016; "BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness," 6/21/2017.)
• Celsius Therapeutics: Apart from collaborations to develop new drugs, Janssen is also applying AI to clinical trials. In July 2019, Celsius Therapeutics announced a partnership with Janssen to use its single-cell genomics and machine learning platform to find predictive biomarkers of response in Janssen’s VEGA study of golimumab (Simponi) and guselkumab (Tremfya) in patients with ulcerative colitis. ("Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis," 7/9/2019; "A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis - Full Text View," 9/7/2018.)
• Iktos: In April 2019, AI-driven drug design startup Iktos announced a collaboration with Janssen. The collaboration will use Iktos' virtual drug design technology on small molecule drug discovery projects. ("Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery," 4/29/2019.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Janssen is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• WinterLight Labs: In January 2018, Johnson Johnson Innovation announced a partnership between Janssen and WinterLight Labs to try predicting dementia and neurodegenerative diseases from voice samples obtained through Janssen clinical trials. ("Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives," 1/5/2018; "Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives | Markets Insider," 1/5/2018.)

Lundbeck

From what I can gather, Lundbeck was a bit later to the game than other pharmaceutical companies when it comes to AI. The earliest reports I can find come from 2017.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Lundbeck:

• IBM: Given that IBM withdrew support for much of its Watson Health work, it's not clear if this partnership still exists. However, in February 2017 IBM announced a collaboration with Lundbeck to analyze information from clinical data through the Watson Health Cloud. The initial focus was deriving new understanding and potential treatments for schizophrenia and Parkinson’s disease. This included through access to anonymous health data for millions of patients in the Watson Health Cloud. ("IBM Watson Health and Lundbeck collaboration on use of artificial intelligence," 2/8/2017.)
• Numerate: In January 2019, Numerate announced a collaboration with Lundbeck to identify drug candidates for central nervous system diseases including depression, psychosis, seizure, and neurodegenerative disorders. ("Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research," 1/7/2019.)

Merck KGaA

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Merck KGaA:

• Cyclica: In December 2018, Merck announced a partnership with Cyclica to use its AI-augmented proteome screening platform to elucidate mechanisms of action, evaluate safety profiles, and explore additional applications for investigational small molecules. ("Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities," 12/6/2018.)
• Iktos: In March 2019, Merck announced a partnership with Iktos to use its generative AI to design novel molecules with desired properties for a specified disease. ("Merck KGaA signs another AI deal," 3/15/2019.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Merck KGaA is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)

Merck and Co.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Merck and Co.:

• Atomwise: Merck (again not clear which one) also has a confidential project with Atomwise ("Partners – Atomwise," 11/13/2019.)
• Numerate: Like Boehringer Ingelheim, Merck (it's not clear which one) struck an early partnership with Numerate, which they announced in March 2012. The collaboration focuses on generating novel small molecule drug leads for an unnamed cardiovascular disease target. ("Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate's In Silico Drug Design Technology," 3/14/2012; "Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate's In Silico Drug Design Technology," 3/14/2012.)
• PathAI: In November 2019, PathAI announced investment from the Merck Global Health Innovation Fund (Merck GHIF) and BMS in its AI-powered pathology platform. ("PathAI Receives Investment from Merck and Bristol-Myers Squibb; Completes $75M Series B," 11/4/2019.)

Mitsubishi Tanabe Pharma

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Mitsubishi Tanabe Pharma:

• Hitachi: Mitsubishi Tanabe Pharma partnered with Hitachi to optimize clinical trial planning with AI. Announced in March 2018, the partnership will use Hitachi’s Lumada platform. It will extract information from scientific papers and ClinicalTrials.gov. A pilot of the technology found time savings of 70%. ("Mitsubishi Tanabe, Hitachi join forces in AI-enabled clinical trials," 3/29/2018.)

Nestlé

While not a traditional pharmaceutical company, Nestlé has a health science division. It aims to advance nutrition as therapy.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Nestlé:

• Nuritas: In February 2018, Nestlé announced a partnership with Nuritas to enlist AI. The partnership will use AI to discover therapeutic peptides in foods ("Nestlé and Nuritas to Work Together on Discovery of Food-Derived Bioactive Peptides Through Artificial Intelligence," 4/26/2018.)

Novartis

On the commercial side, Novartis has been quite innovative in using digital media. Its heavily digital campaign for Gilenya, for example, won multiple awards. Recently, it began making big moves with artificial intelligence. CEO Vas Narasimhan announced in a September 2017 interview that he planned to partner with or acquire AI and data analytics companies. In June 2018, Business Insider published an interview with the outspoken Jay Bradner, president of the Novartis Institutes for BioMedical Research (NIBR), about the company's progress with artificial intelligence. Bradner stated that 4% of the 6,000 scientists working at NIBR are data scientists. "We like to think of ourselves as the lead turtle in the race of the turtles," he said, referring to pharma's conservative adoption of emerging technology. A July 2018 report in InformationWeek highlighted completion of the first phase of Novartis' digital transformation in drug discovery. The company rebuilt its technology infrastructure and connected its data through a single hub. It's now developing a predictive analytics platform that uses machine learning algorithms for clinical trial operations.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Novartis:

• BenchSci: Novartis was one of BenchSci's first customers for its AI-Assisted Antibody Selection product, and the first customer for BenchSci's expansion into other reagents with its AI-Assisted Reagent Selection product. ("BenchSci Raises $22 Million Series B and Launches New AI-Assisted Reagent Selection Product to Optimize $10.2 Billion in Life Science R&D Spend," 2/4/2020.)
• BenevolentAI: BenevolentAI announced a partnership with Novartis to use its AI platform for personalizing oncology treatments ("BenevolentAI announces collaboration with Novartis across multiple drug programmes," 9/5/2019.)
• IBM: A March 2018 report describes a partnership with IBM Watson to improve clinical trial recruitment, and the use of a “digital cortex” to predict medication efficacy. ("AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz," 3/26/2018.)
• Intel: Intel is working with Novartis to apply AI to high content screening ("Intel Adds Memory to Deep Learning for Drug Discovery," 5/31/2018.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Novartis is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): Novartis is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• Microsoft: In September 2019, Novartis announced a significant move to entrench data science and AI within its business: partnering with Microsoft and creating an AI Innovation Lab. The partnership will initially focus on personalized therapies for macular degeneration, cell and gene therapy, and drug design. ("Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence," 10/1/2019.)
• Oxford Big Data Institute: In addition to building in-house AI capabilities, Novartis is partnering with academia. In January 2019, the company announced a partnership with the University of Oxford’s Big Data Institute to predict how patients respond to drugs. The work will combine different types of data, such as clinical, imaging, and genomics data. ("Novartis and Oxford partner on AI in drug development," 1/18/2019.)
• QuantumBlack: In January 2018, an article revealed that Novartis partnered with McKinsey’s QuantumBlack to analyze clinical trial operations with machine learning. They claim the work has reduced patient enrolment times by 10-15%. ("3 things that will change medicine in 2018 | World Economic Forum," 1/24/2018.)

Novo Nordisk

Novo Nordisk included artificial intelligence as a focus of its September 2018 reorganization. The company laid off 400 R&D employees. But it increased investment in artificial intelligence for lead molecule selection and development.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Novo Nordisk:

• e-Therapeutics : In December 2018, Novo announced a deal with UK biotech e-Therapeutics to use its AI-based drug discovery technology to find new treatments for type 2 diabetes. The partnership will include a search for novel intervention strategies, biological pathways, and compounds. It was extended in August 2019 ("Novo begins R&D tie-up with AI biotech e-Therapeutics," 12/12/2018; "Novo extends R&D alliance with AI specialist e-Therapeutics," 8/2/2019.)

Ono Pharmaceuticals

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Ono Pharmaceuticals:

• TwoXAR: One of the largest pharmaceutical companies in Japan, Ono Pharmaceuticals in March 2019 announced a collaboration with twoXAR to discover and develop treatments for an unspecified neurological disease ("Ono Pharmaceutical and twoXAR Announce Drug Discovery Research Collaboration," 3/18/2019.)

Pfizer

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Pfizer:

• Atomwise: In September 2018, Atomwise announced that Pfizer agreed to evaluate its platform. Under the agreement, Atomwise will generate compounds for up to three target proteins. ("Atomwise Enters Into an Evaluation Agreement with Pfizer," 9/17/2018.)
• Concerto HealthAI: In April 2019, Concerto HealthAI announced a partnership with Pfizer to use AI and real world data in oncology. The partnership aims to find actionable insights for Pfizer's investigational and commercialized therapies for solid tumors and hematologic malignancies. ("Concerto HealthAI Enters Precision Oncology Collaboration with Pfizer," 4/9/2019.)
• CytoReason: In January 2019, CytoReason announced a partnership with Pfizer. Details of the partnership were limited. However, CytoReason's technology uses machine learning to understand how cells respond to diseases and treatments. In previous work, the startup has discovered new cellular players in melanoma, new mechanisms of action in atopic dermatitis, and novel pretreatment biomarkers in inflammatory bowel disease anti-TNFα therapy. CytoReason will standardize and organize Pfizer's data and integrate it into a Pfizer-specific immune system model. ("CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery ," 1/7/2019.)
• IBM: Pfizer is one of few companies to publicly promote a drug discovery partnership using IBM Watson. In December 2016, Pfizer and IBM announced a partnership to accelerate drug discovery in immuno-oncology. There has been little announced since (at least, that I can find), but a string of negative reports about IBM Watson's capabilities, including in healthcare, call into question how fruitful the partnership might have been. ("IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery," 12/1/2016.)
• Insilico Medicine: Announced in January 2020, the partnership between Pfizer and Insilico is somewhat vague. Pfizer will reportedly use Insilico's technology to identify real-world evidence for potential targets in various diseases. This seems to center on Insilico's Pandomics platform, which is a standalone product that leverages technology Insilico is developing for drug discovery and development. ("Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets," 1/14/2020.)
• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): Pfizer is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• XtalPi: Pfizer also announced a partnership with XtalPi to combine quantum mechanics and machine learning to predict the properties of drugs. ("Pfizer launches new collaboration with XtalPi for AI drug modeling," 5/9/2018.)

Procter & Gamble

I haven't seen much about P&G's use of artificial intelligence for pharmaceutical products, but A2A Pharma indicates that it has a partnership with them.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Procter & Gamble:

• A2A Pharmaceuticals: According to the pipeline page on A2A Pharma's website, it's collaborating with P&G on a cardiovascular drug.

Roche

Roche has made relatively few big announcements about its use of AI for drug discovery. But I have seen presentations displaying a well-thought-out data management structure. In addition, in February 2018, Roche acquired Flatiron Health, an oncology-focused electronic health records company. Flatiron's massive amount of oncology data provides Roche with a tremendous asset for machine learning. Also, Roche and subsidiary Genentech disclosed a predictive analytics project in September 2019 with a paper in Nature on using deep learning to predict which patients with diabetic retinopathy will progress the fastest.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Roche:

• Owkin: Roche is also one of the few pharmaceutical companies I've seen disclose work with IBM Watson Health. Roche worked with IBM on a study published in January 2019 using real-world data to predict chronic kidney disease in patients with diabetes ("GV invests in medical machine learning startup Owkin," 5/23/2018.)
• Sensyne Health: In December 2019, Sensyne Health announced a partnership with Roche to use AI for identifying patient populations and collating patient data with anonymized electronic health record information for the purpose of planning clinical trials. ("Sensyne Health enters into a research collaboration to apply AI for clinical trial design," 12/23/2019.)

SK Biopharmaceuticals

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for SK Biopharmaceuticals:

• Standigm: SK Group, the South Korean conglomerate that's the parent of SK Biopharmaceuticals, is an investor in AI drug discovery startup Standigm. In November 2019 reports surfaced that it had invested about 10 billion won (USD$8.55 million) to acquire a controlling stake in the company. ("SK boosts biotech capabilities by adding AI-based drug developer," 11/19/2019.)
• TwoXAR: In April 2019, SK Biopharmaceuticals, a Korean company that focuses on disorders of the central nervous system and cancer, announced an agreement with twoXAR to develop new treatments for non-small cell lung cancer. Under the agreement, twoXAR will use its AI discovery technology to identify candidates. SK Biopharmaceuticals will then use its internal AI technology to optimize a lead candidate. ("SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer," 4/17/2019.)

Sanofi

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Sanofi:

• Berg: Sanofi and Berg Health also announced a partnership in October 2017 to assess potential biomarkers for seasonal flu vaccine performance ("BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance," 10/30/2017.)
• Exscientia: Sanofi is also another prominent Exscientia partner. Their partnership, announced in May 2017, focuses on finding bispecific small molecule drugs for metabolic diseases such as diabetes and their comorbidities. In August 2019, Exscientia announced that Sanofi exercised its option for a bispecific small molecule targeting inflammation and the progression of fibrosis. ("Exscientia Announces EUR250 Million Collaboration for a Multiple-Product Development and Licence Option Agreement with Sanofi," 5/9/2017.)
• Google: In June 2019, Sanofi announced what seems like an extensive partnership with Google, including to leverage AI. Through a new virtual "Innovation Lab," Sanofi and Google will analyze real world data to understand what treatments work for patients, and analyze manufacturing and commercial data to forecast sales and inform marketing and supply chain activities. ("Sanofi and Google to develop new healthcare Innovation Lab," 6/18/2019.)
• Inato: Sanofi reportedly has a broad partnership with Inato to find hospitals for clinical trial sites. According to Inato's CEO, Sanofi uses Inato to select sites for "virtually all" of its trials. ("The Sanofi-partnered startup finding clinical trials for the 90%," 2/4/2020.)
• Recursion Pharmaceuticals: In April 2016, Sanofi's Genzyme unit and Recursion Pharmaceuticals announced a partnership to use Recursion's drug repurposing platform to screen Sanofi molecules for genetic disease targets ("Recursion Pharmaceuticals Announces Research Agreement With Sanofi Genzyme," 4/25/2016.)
• Researchably: Sanofi has also experimented with using AI for medical communications. An October 2018 article reported that the company partnered with Researchably, which uses AI to automate medical literature review. Sanofi reportedly found that the software cut the time of reviewing a paper from 13 minutes to less than a second. ("Sanofi taps startup Researchably to use AI to sift through new research," 10/2/2018.)

Santen

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Santen:

• TwoXAR: In February 2017, Japan's Santen, which focuses on ophthalmic products, and TwoXAR announced a partnership to find new drug candidates for glaucoma ("Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments," 2/23/2017.)

Servier

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Servier:

• Iktos: In January 2019, Servier announced successful results from a collaboration with AI drug design startup Iktos. For the collaboration, Servier used Iktos' technology to analyze 800 molecules designed to meet 11 criteria. None of the molecules met all the criteria. Iktos' technology, however, learned from them. It then generated 150 molecules optimized for the criteria. Servier synthesized and tested them, and found that on average, the molecules met 9 of 11 criteria. One met all 11. ("Servier and Iktos announce their successful collaboration in the field of artificial intelligence," 1/29/2019.)
• Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY): Servier is a member of the MELLODDY project, which will train machine learning models on datasets from multiple partners while ensuring the privacy of each partner using federated learning. ("MELLODDY | IMI Innovative Medicines Initiative," 6/1/2019.)
• Numerate: Another partner of the very active Numerate, Servier and the startup announced in June 2017 a collaboration to design small molecule modulators of ryanodine receptor 2 (RyR2), a target thought to be important in cardiovascular disease that has eluded drug-ability. The collaboration could lead to new treatments for heart failure and arrhythmias. ("Numerate and Servier Establish Collaboration to Advance First-in-Class Ryanodine Receptor 2 Candidates for Cardiovascular Diseases," 6/9/2017.)

Sumitomo Dainippon Pharma

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Sumitomo Dainippon Pharma:

• Exscientia: One of Exscientia's early partners, Sumitomo Dainippon and the startup announced in September 2015 initial results of a collaboration to identify new treatments for psychiatric diseases. The first compound identified was a bispecific, dual-agonist molecule that selectively activates two GPCR receptors from two distinct families. In January 2020, the partners announced that their joint compound DSP-1181 was progressing to a phase I trial for obsessive-compulsive disorder. ("Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study," 1/30/2020; "ex scientia Ltd. Partners with Sunovion Pharmaceuticals Inc. to Research New Medicines for Psychiatric Disorders," 11/3/2014.)

Sunovion

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Sunovion:

• Exscientia: In November 2014, Exscientia announced a partnership with Sunovion to research new drugs for psychiatric disorders ("ex scientia, Sunovion Ink $4.8M Psychiatric Drug Discovery Deal," 11/3/2014.)
• Machine Learning for Pharmaceutical Discovery and Synthesis Consortium (MLDPS): Sunovion is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("Applying machine learning to challenges in the pharmaceutical industry," 5/17/2018.)
• PsychoGenics: Sunovion has partnered with PsychoGenics to use the latter's high-throughput platform that combines in vivo behavioral testing with AI to phenotypically discover drug candidates for CNS diseases. In October 2019, PsychoGenics announced receiving milestone payments for two compounds advancing to clinical testing, SEP-378614 and SEP-380135. ("PsychoGenics Announces Milestones Associated with Sunovion’s Advancing Pipeline," 10/30/2019.)

Takeda

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Takeda:

• Massachusetts Institute of Technology: MIT and Takeda began a partnership in January 2020 centered within the Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic). Takeda provided an initial three-year investment with the potential for a two-year extension. The funds will support 6-10 research projects per year, focusing on areas such as disease diagnosis, prediction of treatment response, development of novel biomarkers, process control and improvement, drug discovery, and clinical trial optimization. ("MIT, Takeda Partner to Develop Healthcare Artificial Intelligence," 1/7/2020.)
• Numerate: Another Numerate partner, Takeda and the startup announced in June 2017 that they would collaborate on identifying candidates for oncology, gastroenterology, and central nervous system disorders ("Numerate and Takeda Enter Agreement to Generate Novel Clinical Candidates Using AI-Driven Drug Discovery," 6/12/2017.)
• Recursion Pharmaceuticals: In January 2019, Takeda partner Recursion announced an expanded partnership with the pharmaceutical company to evaluate and identify novel preclinical candidates for rare diseases. The announcement reported that Recursion had evaluated compounds in over 60 indications during the prior 18 months. This reportedly resulted in new therapeutic candidates for more than 6 diseases. Takeda exercised its option for drug candidates in two rare diseases from these early results. ("Recursion Announces Options Exercise by Takeda and Extension of AI-enabled Drug Discovery Collaboration," 1/7/2019.)

Wave Life Sciences

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Wave Life Sciences:

• Deep Genomics: In May 2018, Wave and Deep Genomics announced a collaboration to use machine learning to find new treatments for genetic neuromuscular disorders ("Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders," 4/10/2018.)

WuXi AppTec

WuXi AppTec Group is a global pharmaceutical, biopharmaceutical, and medical device company.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for WuXi AppTec:

• Adagene: In June 2016, Adagene, which applies machine learning to the development of novel therapeutic antibodies, announced investment from WuXi Apptec as part of its series B funding. ("Adagene Raises $28 Million in Series B Funding," 1/28/2016.)
• Insilico Medicine: In June 2018, WuXi AppTec became an investor in Insilico Medicine. It has also partnered with Insilico to develop some of its technology. This includes Insilico's GENTRL platform, which applies generative adversarial networks and generative reinforcement learning to drug discovery, as announced in September 2019. ("WuXi AppTec Leads Strategic Investment in Insilico Medicine to Accelerate Drug Discovery Using Next-Generation Artificial Intelligence," 6/1/2018; "Insilico Medicine Develops and Validates Powerful AI System To Transform Drug Discovery," 9/2/2019.)

Yuhan Corp.

Yuhan is a South Korean pharmaceutical and chemical company.

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Yuhan Corp.:

• Cyclica: In November 2019, Yuhan announced a partnership with Cyclica to use the latter's AI-based candidate discovery platform fro two selected R&D programs. These programs weren't disclosed. ("Yuhan Corp. to Carry out AI-based New Drug Development Jointly with Canada’s Cyclica," 11/8/2019.)

Zambon Pharma

Here are relevant partnerships, investments, joint ventures, and memberships I'm aware of for Zambon Pharma:

• GNS Healthcare: Zambon Pharma is a member of MLDPS, which is a collaboration with MIT to develop software for automating small molecule discovery and synthesis. ("GNS Healthcare Adds $6M, Led by Amgen, for Machine Learning Tech," 8/23/2017.)

Anything I’ve missed? Let me know in the comments. Add anything I left out or got wrong for the companies above. Or tell me about companies I haven't listed yet.

Craving more information? Check out my posts on startups using AI in drug discovery and AI in drug discovery trends and statistics.

Credits: Logos provided by Clearbit.